Developmental Changes in Drug Transporters Across Childhood

Abstract

Drug transporters are integral to pharmacokinetics, influencing the absorption, distribution, and elimination of medications. Their ontogeny how expression and function change across developmental stages has significant implications for pediatric clinical pharmacology. This review synthesizes recent advances in understanding developmental changes in key drug transporters across childhood, highlights their impact on drug disposition, and provides clinicians with practical guidance for individualized pediatric dosing based on transporter maturation.

Introduction

Pediatric patients are not small adults; their unique physiology necessitates careful consideration in drug therapy. Drug transporters, including solute carrier (SLC) and ATP-binding cassette (ABC) families, are pivotal in mediating cellular drug uptake and efflux. Their expression and activity undergo significant developmental modulation, affecting drug exposure and therapeutic outcomes. An evidence-based grasp of these changes is essential for optimizing pediatric pharmacotherapy, minimizing toxicity, and enhancing efficacy.

Epidemiology / Disease Burden

Globally, millions of children require medications annually, with a substantial proportion prescribed off-label due to limited pediatric pharmacokinetic data. Inadequate understanding of drug transporter ontogeny contributes to variability in drug response, adverse effects, and therapeutic failure. Neonates and infants, in particular, are vulnerable to altered drug handling due to immature transporter expression, underscoring the need for age-appropriate dosing strategies. Epidemiological studies have identified that transporter-mediated pharmacokinetic differences account for a considerable proportion of pediatric adverse drug reactions, especially in neonatology and pediatric oncology.

Pathophysiology

Drug transporters such as P-glycoprotein (P-gp/ABCB1), organic anion transporting polypeptides (OATPs), and multidrug resistance-associated proteins (MRPs) are expressed in critical organs including the liver, kidney, intestine, and blood-brain barrier. In early life, transporter expression is tightly regulated by developmental cues, transcriptional modulators, and epigenetic mechanisms. For example, hepatic OATP1B1 and OATP1B3 expression is low at birth but increases substantially during infancy and childhood, influencing the hepatic uptake and clearance of drugs like statins and certain anticancer agents. Conversely, renal organic cation transporters (OCTs) demonstrate a delayed maturation profile, impacting the excretion of metformin and other cationic drugs. The ontogeny of these transporters is non-linear and transporter-specific, adding complexity to pediatric pharmacokinetics.

Risk Factors

Several factors modulate transporter expression and function in children. Genetic polymorphisms can confer significantly altered transporter activity, as seen with ABCB1 variants impacting central nervous system drug penetration. Co-morbidities such as liver or renal dysfunction further perturb transporter-mediated drug handling. Additionally, environmental exposures, nutrition, and concomitant medications may induce or inhibit transporter expression, compounding the risk of unpredictable drug responses. Prematurity and perinatal insults are particularly impactful, often resulting in delayed transporter maturation and increased susceptibility to drug toxicity.

Clinical Features

Clinical manifestations of altered drug transporter function are diverse. In neonates, impaired P-gp activity at the blood-brain barrier can result in increased central nervous system exposure to drugs such as morphine, raising the risk for sedation or respiratory depression. In older children, maturation of hepatic uptake transporters correlates with improved drug clearance and reduced toxicity. However, inter-individual variability remains high, necessitating vigilant therapeutic monitoring. Drug-drug interactions involving transporter substrates, inhibitors, or inducers are increasingly recognized as contributors to adverse drug events in pediatric populations.

Diagnosis

Diagnosing transporter-related pharmacokinetic aberrations relies on a combination of clinical suspicion, therapeutic drug monitoring, and where available pharmacogenetic testing. Measuring plasma concentrations of drugs with narrow therapeutic indices (e.g., immunosuppressants, antiepileptics) can help identify atypical pharmacokinetics suggestive of transporter involvement. Advanced analytical methods, such as LC-MS/MS quantification of drug and metabolite profiles, are increasingly utilized in pediatric pharmacology research to characterize transporter function in vivo. Genotyping for common transporter polymorphisms may be warranted in cases of unexplained drug toxicity or subtherapeutic response.

Treatment & Management

Optimizing drug therapy in children requires an individualized approach, considering age-dependent transporter expression, genetic background, organ function, and potential for drug-drug interactions. Dose adjustments based on developmental pharmacokinetic models are recommended for drugs with transporter-mediated disposition. In neonates and infants, lower transporter activity may necessitate reduced dosing or extended dosing intervals to prevent accumulation and toxicity. Ongoing monitoring of drug levels and clinical response is critical, particularly for drugs with narrow therapeutic windows or significant transporter involvement. Interdisciplinary collaboration among pediatricians, pharmacists, and clinical pharmacologists is essential for safe and effective therapy.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in elucidating transporter ontogeny using transcriptomic, proteomic, and functional studies. Human pediatric tissue biobanking and in vitro models have enabled direct assessment of age-related transporter expression, while population pharmacokinetic modeling integrates these data into dose optimization algorithms. Novel imaging modalities, such as PET tracers for transporter activity, hold promise for noninvasive in vivo assessment. Emerging gene editing and mRNA-based therapeutics targeting transporter regulation represent future avenues for modulating drug disposition in pediatric disease. Current research efforts also focus on developing transporter-specific probes to refine pediatric pharmacogenomic testing.

Guideline Recommendations

International guidelines, including those from the FDA and EMA, underscore the importance of integrating transporter ontogeny data into pediatric drug development and labeling. Recommendations emphasize age-stratified pharmacokinetic studies, incorporation of transporter genotyping in precision medicine initiatives, and ongoing post-marketing surveillance for transporter-mediated adverse events. Clinical practice should prioritize evidence-based dosing regimens, utilize therapeutic drug monitoring for high-risk drugs, and consider pharmacogenetic testing in children with unexplained drug response variability.

Conclusion

Understanding the developmental dynamics of drug transporters is crucial for optimizing pediatric pharmacotherapy. Age-dependent changes in transporter expression and function significantly influence drug absorption, distribution, and elimination, contributing to inter-individual variability in response and safety. Incorporating transporter ontogeny into clinical practice enables rational dosing, improved efficacy, and reduced risk of adverse events in children. Ongoing research and guideline development will further enhance the precision of pediatric drug therapy, ensuring the safe and effective use of medications across all stages of childhood.